It is significantly lower on the MCF-7 cells isn't it.... then you take into consideration patients can handle 4 or 5 times more Bisantrane than Doxo (from memory) and it makes it even more significant..
IMO, DYOR, etc
Ann: Compelling Preclinical Breast Cancer Results, page-196
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.50 |
Change
0.055(3.82%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.50 | $1.46 | $50.72K | 34.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6138 | $1.48 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.50 | 1400 | 1 |
View Market Depth
| Last trade - 10.10am 12/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |